SEP 3·SEC EDGARLow
HIRSCHHORN MARK sold $127K of AMWL
HIRSCHHORN MARK (Chief Financial Officer) sold 10,751 shares of American Well Corp (AMWL) at $11.80 ($0.13M total) on 2026-09-01.
StockNYSE · US · USDHealthcare · Health Information Services
$AMWL
American Well Corp
Price · $AMWLvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $AMWL in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $170K 3 txs
McNeice Paul Francis1× · $1K
10b5-1 share of filings0%
Top stories · $AMWLMore →
AUG 12·fool.com
American Well (AMWL) Q2 2026 Earnings Call Transcript
American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.
AUG 6·rttnews.com
Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
AMWL sentiment & insider activity
Recent AMWL coverage spans market movers, insider activity and earnings.
In the last 30 days, AMWL insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($170K). The most active reporter was McNeice Paul Francis, Chief Accounting Officer, with 1 filing.
What's driving AMWL
Insider sale by CFO may signal reduced confidence, but size is modest.
Guidance raises and a Defense Health Agency sole-source intent are likely to support near-term sentiment, but Q3 EBITDA loss guidance and churn keep risk elevated.
The trade is profitability improvement versus declining revenue, with Q3 guidance setting the near-term ceiling.
The article is a sell-side target revision story, not a fundamental company disclosure. It can still move near-term sentiment and positioning if traders treat PT changes as a proxy for improving outlook.
Guidance raise plus improving adjusted EBITDA trajectory suggests improving operating leverage, but GAAP remains loss-making.
AlphAI scores every news story that mentions AMWL with an AI model for sentiment and relevance, and aggregates insider trades from American Well Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AMWL
Score
HIRSCHHORN MARK sold $127K of AMWL
HIRSCHHORN MARK (Chief Financial Officer) sold 10,751 shares of American Well Corp (AMWL) at $11.80 ($0.13M total) on 2026-09-01.
1 min read
American Well (AMWL) Q2 2026 Earnings Call Transcript
American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.
6 min readTop Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min read
American Well Corporation Stock 12‑Month Price Target Raised to $11.58, Implies 11% Upside
Analyst estimates cited by FactSet show American Well Corp’s 12-month average price target increased from $8.50 to $11.58. The range is $7.50 to $16. Based on the Aug. 4 close, the target implies about 11% upside. The consensus rating remains “Hold” (1 Buy, 7 Hold, 0 Sell) across 8 analysts.
1 min readAmerican Well Corp (AMWL): Results of Operations and Financial Condition
American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026
4 min readAmerican Well Corp (AMWL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
American Well Corp (AMWL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001393584 false 0001393584 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08,
2 min readTop Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus
Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.
7 min readBiotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH
Biotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.
5 min readAmerican Well Corp (AMWL): Submission of Matters to a Vote of Security Holders
American Well Corp (AMWL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001393584 0001393584 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,
2 min readHIRSCHHORN MARK sold $105K of AMWL
HIRSCHHORN MARK (Chief Financial Officer) sold 10,761 shares of American Well Corp (AMWL) at $9.74 ($0.10M total) on 2026-06-01.
1 min read